A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging Phase 2 Study to Evaluate Different Doses of ZL-1102 Topical Gel in Chronic Plaque Psoriasis

What this Trial Is About

Researchers are evaluating the safety and effectiveness of different doses of ZL-1102 topical gel in treating adults with chronic plaque psoriasis. This phase 2 study is randomized, double-blind, and vehicle-controlled, involving around 250 participants to compare multiple doses of ZL-1102 against a placebo gel over 16 weeks. Participants will be assigned to one of five groups receiving either ZL-1102 gel at varying doses and frequencies or a matching placebo gel. The treatments include ZL-1102 1 gel applied twice daily, ZL-1102 3 gel applied once or twice daily, or placebo gel applied once or twice daily. The treatment period lasts for 16 weeks, followed by assessments. During the study, participants will undergo regular evaluations including assessments of psoriasis severity using tools like IGA and mPASI scores. Researchers will monitor treatment efficacy, skin tolerability, serum drug levels, and potential side effects through week 20. Participants will be followed closely to measure improvements and adverse events, ensuring comprehensive safety monitoring throughout the study duration.

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis